Edition:
United Kingdom

Immunovia AB (publ) (IMMNOV.ST)

IMMNOV.ST on Stockholm Stock Exchange

160.20SEK
10:28am BST
Change (% chg)

-1.80kr (-1.11%)
Prev Close
162.00kr
Open
161.80kr
Day's High
162.40kr
Day's Low
157.00kr
Volume
10,801
Avg. Vol
16,643
52-wk High
273.50kr
52-wk Low
127.80kr

Latest Key Developments (Source: Significant Developments)

Immunovia Q3 Net Loss Widens To SEK 17.4 Mln
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Immunovia AB (publ) ::IMMUNOVIA'S TARGET IS TO ACHIEVE TURNOVER OF SEK 250-300 MILLION BY 2022 BASED ON SELF-PAY FOR IMMRAY™ PANCAN -D.TO ACHIEVE TOTAL TURNOVER, INCLUDING PAYMENT VIA SELF-PAY AND COST REMUNERATION FROM INSURANCE SYSTEMS, OF SEK 800-1,000 MILLION BY 2024.Q3 NET LOSS SEK 17.4 MILLION VERSUS LOSS SEK 11.6 MILLION YEAR AGO.JULY-SEPT NET SALES AT SEK 85,000 VERSUS SEK 27,000 YEAR AGO.  Full Article

Immunovia Q1 Operating Loss Widens To SEK 17.4 Million
Friday, 27 Apr 2018 

April 27 (Reuters) - IMMUNOVIA AB (PUBL) ::Q1 NET SALES SEK 112,000 VERSUS SEK 28,000 YEAR AGO.COMPANY HAS A TARGET OF ACHIEVING TURNOVER OF SEK 250-300 MILLION BY 2021.TARGET OF TOTAL TURNOVER OF SEK 800-1,000 BY 2023.Q1 OPERATING LOSS SEK 17.4 MILLION VERSUS LOSS SEK 7.9 MILLION YEAR AGO.  Full Article

Immunovia Aims To Reach SEK 250-300 Million In Turnover In 2021​
Monday, 12 Mar 2018 

March 12 (Reuters) - IMMUNOVIA AB (PUBL) ::IMMUNOVIA ANNOUNCES FINANCIAL TARGETS.‍GOAL IS TO REACH SEK 250-300 MILLION IN TURNOVER IN 2021​.‍GOAL IS TO REACH TURNOVER OF SEK 800-1,000 MILLION IN 2023​.‍EXPECTS FIRST REVENUES FROM SELF-PAY SALES DURING Q4 OF 2018​.TARGET OF SEK 250-300 MILLION IN TURNOVER IN 2021,.TO ACHIEVE A TURNOVER OF SEK 250-300 MILLION IN 2021 BASED ON SELF-PAY FOR IMMRAY™ PANCAN-D..  Full Article

Immunovia AB Q4 Net Sales Sek ‍​ 26,000 Versus Sek 106,000 Year Ago
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - IMMUNOVIA AB ::Q4 NET SALES SEK ‍​ 26,000 VERSUS SEK 106,000 YEAR AGO.Q4 PRETAX LOSS SEK ‍​ 15.3 MILLION VERSUS LOSS SEK 5.4 MILLION YEAR AGO.  Full Article

Immunovia Q3 net loss widens to SEK 11.6 mln‍​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - IMMUNOVIA AB (PUBL) :NET SALES FOR Q3 2017 WERE SEK 27 THOUSAND (5 K)‍​.THE NET LOSS FOR Q3 2017 WAS SEK 11,589 THOUSAND (-4,048 K)‍​.  Full Article

Immunovia gets SEK 4.9 mln grant from Swelife Accelerator Innovation Program
Monday, 30 Oct 2017 

Oct 30 (Reuters) - IMMUNOVIA AB (PUBL) ::IMMUNOVIA RECEIVES SEK4.9 MILLION GRANT FROM SWELIFE ACCELERATOR INNOVATION PROGRAM.  Full Article

Immunovia starts cooperation with ‍Linköping University Medical Faculty ​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - IMMUNOVIA AB (PUBL) :STARTS COOPERATION WITH ‍LINKÖPING UNIVERSITY MEDICAL FACULTY ​.  Full Article

Immunovia announces cooperation with Lund University on diabetes research ‍​
Thursday, 7 Sep 2017 

Sept 7 (Reuters) - IMMUNOVIA AB (PUBL) ::ANNOUNCES COOPERATION WITH LUND UNIVERSITY ON DIABETES RESEARCH ‍​.  Full Article

Immunovia Q2 operating loss widens to SEK 10.6‍​ million
Wednesday, 23 Aug 2017 

Aug 23 (Reuters) - IMMUNOVIA AB (PUBL) :Q2 NET SALES SEK 68,000‍​ VERSUS SEK 66,000 YEAR AGO.Q2 OPERATING LOSS SEK 10.6‍​ MILLION VERSUS LOSS SEK 3.0 MILLION YEAR AGO.  Full Article

Immunovia establishes US headquarters in Boston, Massachusetts
Wednesday, 28 Jun 2017 

June 28 (Reuters) - IMMUNOVIA AB (PUBL) :IMMUNOVIA ESTABLISHES US HEADQUARTERS, INCLUDING CLIA REFERENCE LABORATORY, IN BOSTON.‍BOSTON, MASSACHUSETTS USA, HAS BEEN CHOSEN AS LOCATION FOR HEADQUARTERS OF IMMUNOVIA INC, A WHOLLY OWNED SUBSIDIARY.  Full Article

BRIEF-Immunovia Q4 Pretax Loss Widens To SEK 25.7 Mln

* REPORTED ON THURSDAY Q4 NET SALES SEK 91,000 VS SEK 26,000 YR AGO